Tube Investments of India Limited reported a revenue of ₹2,119 Crores for Q2 FY2026, compared to ₹2,065 Crores in the same period last year. Profit Before Tax (PBT) stood at ₹250 Crores, up from ₹225 Crores. Consolidated revenue reached ₹5,523 Crores, with a PBT of ₹459 Crores. The company anticipates significant growth in key segments, including mobility and medical, driven by market share gains and strategic initiatives.

Financial Performance

In Q2 FY2026, Tube Investments of India’s standalone revenue reached ₹2,119 Crores, marking an increase from ₹2,065 Crores in the corresponding period of the previous year. The company’s Profit Before Tax (PBT) increased to ₹250 Crores, compared to ₹225 Crores in the same quarter of the previous year, reflecting a growth of 11.5%. ROIC was at 44%.

The consolidated revenue stood at ₹5,523 Crores compared to ₹4,925 Crores. Profit before tax for the quarter was at ₹459 Crores as against ₹426 Crores in the corresponding quarter.

Segmental Performance

Engineering business revenue for the quarter reached ₹1,382 Crores, compared to ₹1,323 Crores in the corresponding quarter. PBIT was ₹164 Crores.

Metal formed products generated revenue of ₹408 Crores. PBIT was ₹44 Crores.

The mobility business, which includes bicycles, reported revenue of ₹194 Crores, compared to ₹168 Crores. PBIT stood at ₹4 Crores.

Other businesses generated revenue of ₹227 Crores, with PBIT at ₹18 Crores.

Key Growth Drivers & Future Outlook

The company witnessed a strong uptick in demand after changes in September 2025, coupled with the festive season. October and November have shown strong performance. The company is targeting a growth of 15% plus for the surgical business. They are also exploring new verticals for TI Medical.

For base business, the company is going to invest next year about ₹300 to 400 Crores. In mobility division, their focus was more towards the specialized bike and they are focusing on the fitness side of the business.

Source: BSE

Godfrey Phillips India has received an order from the tax authority demanding GST, along with interest and penalties. The total demand and penalty each amount to ₹43,60,652. The company is assessing its options, including filing an appeal, and believes the order will not have a material impact on its financials or operations.

GST Order Received

Godfrey Phillips India announced today, November 11, 2025, that it has received an order related to the Central Goods and Services Tax (GST) Act, 2017. The order was issued by the Assistant Commissioner of CGST Division, Rohtak, Haryana, and was received on November 10, 2025.

Details of Demand and Penalty

The order demands GST, along with applicable interest and imposes a penalty of ₹43,60,652 on the company. An equivalent penalty of ₹43,60,652 has also been levied on a former independent director of the Company. This is under the Central Goods and Services Tax Act, 2017 and the Haryana Goods and Services Tax Act, 2017, read with the Integrated Goods and Services Tax Act, 2017.

Alleged Violation and Company Response

The demand relates to alleged irregular availment and utilization of Input Tax Credit (ITC) under the GST laws. Godfrey Phillips India maintains that the order will not have a material impact on the financials, operations, or other activities of the company. The company is currently evaluating all available options, including the possibility of filing an appeal against the order.

Source: BSE

Sai Life Sciences plans to recruit 200 scientists in November 2025 to meet increasing demand for its Discovery and CMC services. The company will conduct walk-in interviews in Bengaluru on November 15–16, 2025. This recruitment aims to support the company’s expanding operations and its commitment to solving complex scientific challenges and delivering innovative medicines.

Recruitment Drive Announcement

Sai Life Sciences is set to recruit 200 scientists in November 2025, aiming to meet the increasing demand for Discovery and CMC services. Walk-in interviews will be held in Bengaluru on November 15-16, 2025, at Sai Vishram Business Hotel, Hebbagodi, from 9:00 a.m. to 5:00 p.m.

Available Positions

The open positions include various scientific functions such as Process R&D, Analytical R&D, Process Engineering, Biology (in vitro and in vivo), and DMPK. Candidates with qualifications like M.Sc., M.Pharm, B.E. / M.E. (Chemical Engineering), or Ph.D. in relevant areas are encouraged to apply. Professionals with 2-14 years of experience can participate.

Expansion and Capabilities

This recruitment drive supports the company’s expanding operations. Sai Life Sciences is building an ecosystem for scientists to solve complex scientific challenges and contribute to patients’ lives. The company is expanding its capacity and capability. The new CMC Process R&D Center is scheduled for completion by September 2026. Earlier this year, the company expanded its Integrated Discovery platform with the launch of a biology facility.

Company Overview

Sai Life Sciences partners with more than 300 global innovators, including 18 of the top 20 pharmaceutical companies, to accelerate the discovery, development, and commercialization of complex small molecules.

Source: BSE

Granules India’s subsidiary, Granules Life Sciences Private Limited (GLS) in Hyderabad, has received its first U.S. Food and Drug Administration (FDA) approval. The approval follows a Pre-Approval Inspection (PAI) conducted between July 28 and August 1, 2025. The company plans to soon launch the approved product in the U.S. market, complementing existing production at its Gagillapur facility. This marks a significant milestone for expanding manufacturing capabilities.

Hyderabad Facility Gains Approval

Granules India Limited announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has received U.S. FDA approval for a product following a successful Pre-Approval Inspection (PAI) conducted between July 28th and August 1st, 2025.

Inspection Details

During the inspection, there was one observation, to which GLS promptly submitted its response within the stipulated timeframe.

Significance of the Approval

The FDA approval signifies a major achievement for Granules India, enhancing its finished dosage manufacturing capabilities. This marks the first FDA approval for the GLS site.

Launch Plans

The company plans to launch the approved product in the U.S. market shortly. This product is already manufactured at Granules’ Gagillapur facility. This approval will help increase market share and support business continuity across multiple manufacturing locations.

Executive Commentary

Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited, commented, “We plan on launching the product into the U.S. market soon. It is an already approved product at our Gagillapur facility, but we plan on building market share with this approval. We also have other products filed from this site and expect the U.S. FDA to approve them following necessary audits if required. This marks the first approval from our second Hyderabad facility with finished dosage capabilities.”

Source: BSE

Infosys has been recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for Public Cloud IT Transformation Services for the third consecutive year. The recognition highlights Infosys’ consistent excellence in delivering transformational outcomes through cloud-native professional and managed services and its strategic investments in cloud innovation and enterprise automation, reinforcing the trust that clients place in Infosys.

Gartner Recognition

Infosys announced its recognition as a Leader in the 2025 Gartner® Magic Quadrant™ for Public Cloud IT Transformation Services (PCITS). This marks the third consecutive year Infosys has achieved this recognition.

Driving Cloud and AI Innovation

This acknowledgment underscores Infosys’ consistent ability to deliver transformational results using cloud-native professional and managed services. It highlights the company’s strategic investments in cloud innovation and enterprise automation. Infosys Cobalt continues to be a key accelerator for enterprise cloud journeys, emphasizing zero-touch operations, automated healing, and AlOps-driven resiliency.

Executive Perspective

Anant Adya, EVP and Service Offering Head, Infosys, stated that the recognition reaffirms the trust clients place in Infosys. He further emphasized that Infosys, with Infosys Cobalt, is not only guiding clients through cloud, data, and Enterprise Al transformation but also co-innovating with them to build the digital businesses of the future.

Source: BSE

Info Edge (India) Limited announced that SES ESG Research Private Limited has independently assigned an ESG rating of 74.4 (Adjusted) for FY 2024-25. This is an increase from the ESG rating of 71.2 (Adjusted) for FY 2023-24. SES ESG independently prepared and voluntarily issued the report based on Info Edge’s disclosures for fiscal years 2024 and 2025.

ESG Rating Upgrade

Info Edge has received an increased ESG rating from SES ESG Research Private Limited. The rating for FY 2024-25 is 74.4 (Adjusted), up from 71.2 (Adjusted) in FY 2023-24. This rating reflects the company’s performance in Environmental, Social, and Governance factors.

Independent Assessment

The ESG rating was independently assigned by SES ESG Research, a SEBI-registered Category-II entity. The assessment was based solely on publicly available data and the company’s disclosures for fiscal 2024 and 2025. Info Edge has not engaged SES for ESG Rating; instead, SES prepared the report independently.

Communication Details

The communication from SES was received by Info Edge on November 10, 2025, at 9:05 P.M. IST. The information is also available on the company website.

Source: BSE

Zydus Lifesciences has received approval from China’s National Medical Products Administration (NMPA) for Venlafaxine Extended-Release (ER) Capsules in 75 mg and 150 mg dosages. These capsules are used to treat Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). This marks the first approval Zydus has received from the NMPA in China, with production to take place at its Moraiya, Ahmedabad facility.

China Approval Received

Zydus Lifesciences has secured approval from China’s National Medical Products Administration (NMPA) for its Venlafaxine Extended-Release (ER) Capsules, available in 75 mg and 150 mg strengths. This approval, announced on November 11, 2025, represents a significant milestone for Zydus in expanding its global reach.

Therapeutic Uses

Venlafaxine ER Capsules are prescribed for the treatment of various mental health conditions, including:

• Major Depressive Disorder (MDD)
• Generalised Anxiety Disorder (GAD)
• Social Anxiety Disorder (SAD)
• Panic Disorder (PD)

These capsules function by helping to restore the balance of serotonin and norepinephrine in the brain, which can improve mood and reduce anxiety.

Manufacturing Location

The Venlafaxine ER Capsules will be manufactured at Zydus’ production facility located in Moraiya, Ahmedabad. This reflects the company’s commitment to producing high-quality medications for global markets. This is the first approval that the Group has received from NMPA in China.

Source: BSE

ACME Solar has been awarded a 450 MW – 1800 MWh assured peak power SJVN FDRE-IV project at a tariff of INR 6.75/unit for 25 years. The project integrates 300 MW of Solar and Battery Energy Storage System (BESS) technology of approximately 1800 MWh, focusing specifically on peak power supply to support grid stability.

Project Award Overview

ACME Solar has secured a 450 MW – 1800 MWh assured peak power SJVN FDRE-IV project. The project was awarded on November 10, 2025, with a tariff set at INR 6.75 per unit for a duration of 25 years. The e-reverse auction for the tender occurred on October 9, 2025, and the Letter of Award (LoA) was received on November 10, 2025.

Project Details and Integration

The project mandates the supply of power at 4 MWh per MW of capacity during any four-hour period within the peak demand window, ensuring 90% availability monthly. The integration will include 300 MW of Solar power along with a Battery Energy Storage System (BESS) using approximately 1800 MWh of technology to meet supply demands.

Strategic Focus

This initiative focuses on peak power supply, aiming to bolster grid stability and effectively manage critical peak demand. It leverages night-time connectivity available with ACME Solar in high irradiation zones within Rajasthan. Notably, this marks ACME Solar’s inaugural project utilizing Indian-made solar cells under the ALMM List-II.

Executive Commentary

According to Mr. Rahula Kashyapa, Chief Commercial Officer at ACME Solar, securing the SJVN FDRE-IV project with peak power efficiently uses available transmission capacity from night time connectivity. This approach enables the company to realize early revenue, creating a beneficial outcome for both the customer and ACME Solar.

Source: BSE

Reliance Power’s subsidiary, Reliance NU Energies, has received a Letter of Award for a significant renewable energy project. The company secured 750 MW / 3000 MWh, representing 50% of the total tender allocation in a competitive bidding process. The project will feature an installed capacity of 900 MWp of solar power integrated with over 3,000 MWh of Battery Energy Storage System (BESS).

Reliance NU Energies Project Win

Reliance NU Energies Private Limited, a wholly-owned subsidiary of Reliance Power Limited, has been awarded a Letter of Award (LOA) on November 10, 2025. The company emerged as the largest winner in the 1500 MW / 6000 MWh Firm and Dispatchable Renewable Energy (FDRE) ISTS tender issued by SJVN Limited.

Project Details

Reliance NU Energies secured a capacity of 750 MW / 3,000 MWh, representing the largest single share of allocation under the tender. This achievement reinforces Reliance Group’s position as a key player in the renewable energy sector.

India’s Largest Solar + BESS Player

The Reliance Group has consolidated its position as India’s largest player in the Solar + BESS segment, with a cumulative portfolio exceeding 4 GWp of solar and 6.5 GWh of BESS across 4 tenders, under development and implementation. This milestone, accomplished in just 10 months, highlights the Group’s rapid execution capabilities.

Project Capacity and Tariff

The project will feature an installed capacity of 900 MWp of solar power integrated with over 3,000 MWh of BESS. Reliance NU Energies successfully secured a tariff of ₹6.74 per KWh through a competitive bidding online auction process.

Source: BSE